CNTN2
Contactin-2
Also known as: AXT, CNTN2_HUMAN, TAG-1, TAX, TAX1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q02246
- Gene
- CNTN2
- Ensembl
- ENSG00000184144
- Chromosome
- 1
- Canonical length
- 1040 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters
- Secretome location
- Secreted in brain
OverviewNCBI Gene
This gene encodes a member of the contactin family of proteins, part of the immunoglobulin superfamily of cell adhesion molecules. The encoded glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein plays a role in the proliferation, migration, and axon guidance of neurons of the developing cerebellum. A mutation in this gene may be associated with adult myoclonic epilepsy. [provided by RefSeq, Sep 2016]
Canonical amino-acid sequenceUniProt
1040 residues, UniProt reviewed canonical sequence.
>Q02246|CNTN2
1 MGTATRRKPH LLLVAAVALV SSSAWSSALG SQTTFGPVFE DQPLSVLFPE ESTEEQVLLA
61 CRARASPPAT YRWKMNGTEM KLEPGSRHQL VGGNLVIMNP TKAQDAGVYQ CLASNPVGTV
121 VSREAILRFG FLQEFSKEER DPVKAHEGWG VMLPCNPPAH YPGLSYRWLL NEFPNFIPTD
181 GRHFVSQTTG NLYIARTNAS DLGNYSCLAT SHMDFSTKSV FSKFAQLNLA AEDTRLFAPS
241 IKARFPAETY ALVGQQVTLE CFAFGNPVPR IKWRKVDGSL SPQWTTAEPT LQIPSVSFED
301 EGTYECEAEN SKGRDTVQGR IIVQAQPEWL KVISDTEADI GSNLRWGCAA AGKPRPTVRW
361 LRNGEPLASQ NRVEVLAGDL RFSKLSLEDS GMYQCVAENK HGTIYASAEL AVQALAPDFR
421 LNPVRRLIPA ARGGEILIPC QPRAAPKAVV LWSKGTEILV NSSRVTVTPD GTLIIRNISR
481 SDEGKYTCFA ENFMGKANST GILSVRDATK ITLAPSSADI NLGDNLTLQC HASHDPTMDL
541 TFTWTLDDFP IDFDKPGGHY RRTNVKETIG DLTILNAQLR HGGKYTCMAQ TVVDSASKEA
601 TVLVRGPPGP PGGVVVRDIG DTTIQLSWSR GFDNHSPIAK YTLQARTPPA GKWKQVRTNP
661 ANIEGNAETA QVLGLTPWMD YEFRVIASNI LGTGEPSGPS SKIRTREAAP SVAPSGLSGG
721 GGAPGELIVN WTPMSREYQN GDGFGYLLSF RRQGSTHWQT ARVPGADAQY FVYSNESVRP
781 YTPFEVKIRS YNRRGDGPES LTALVYSAEE EPRVAPTKVW AKGVSSSEMN VTWEPVQQDM
841 NGILLGYEIR YWKAGDKEAA ADRVRTAGLD TSARVSGLHP NTKYHVTVRA YNRAGTGPAS
901 PSANATTMKP PPRRPPGNIS WTFSSSSLSI KWDPVVPFRN ESAVTGYKML YQNDLHLTPT
961 LHLTGKNWIE IPVPEDIGHA LVQIRTTGPG GDGIPAEVHI VRNGGTSMMV ENMAVRPAPH
1021 PGTVISHSVA MLILIGSLELLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CNTN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 157 nTPM
Expression across tissuesHPA
Tissue
- spinal cord: 157 nTPM
- midbrain: 87 nTPM
- hippocampal formation: 71 nTPM
- basal ganglia: 50 nTPM
- cerebral cortex: 45 nTPM
- hypothalamus: 41 nTPM
Single-cell type
- oligodendrocytes: 427 nCPM
- schwann cells: 58 nCPM
- thyrotrophs: 57 nCPM
- late spermatids: 50 nCPM
- somatotrophs: 36 nCPM
- retinal amacrine cells: 23 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 449 nTPM
- medulla oblongata: 286 nTPM
- basal ganglia: 245 nTPM
- cerebral cortex: 217 nTPM
- pons: 214 nTPM
- midbrain: 213 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CNTN2.
Disease | AllUniProt
Conditions CNTN2 is implicated in, by any mechanism.
- Epilepsy, early-onset, 5, with or without developmental delay (EPEO5) MIM:615400
Disease | GeneticClinVar
41 pathogenic / likely-pathogenic of 881 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Epilepsy, familial adult myoclonic, 5
- Complex neurodevelopmental disorder
Disease | ImmuneIEDB
Conditions an epitope on CNTN2 was assayed in.
- narcolepsy B cell
- multiple sclerosis B cell
- peripheral nervous system disease B cell
- sleep disorder B cell
ReferencesPubMed · IEDB
Publications for CNTN2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.
2018 · JAMA Neurol · RCR 2.1 · 42 citations - Neuronal antibodies in pediatric epilepsy: Clinical features and long-term outcomes of a historical cohort not treated with immunotherapy.
2016 · Epilepsia · RCR 1.4 · 30 citations - Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis.
2012 · J Neuroimmunol · RCR 0.7 · 25 citations
Reference: B cellIEDB
2 publications
- Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy.
2017 · J Proteome Res · RCR 2.2 · 57 citations - Absence of specific autoantibodies in patients with narcolepsy type 1 as indicated by an unbiased random peptide-displayed phage screening.
2024 · PLoS One · RCR 0.4 · 2 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.44
- gnomAD pLI
- 0
- gnomAD missense Z
- 2.59
- DepMap mean gene effect
- 0.09
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adult walking behavior
- axon guidance
- axonal fasciculation
- cell adhesion
- central nervous system myelination
- cerebral cortex GABAergic interneuron migration
- clustering of voltage-gated potassium channels
- dendrite self-avoidance
- establishment of localization in cell
- fat cell differentiation
- G protein-coupled adenosine receptor signaling pathway
- homophilic cell adhesion via plasma membrane adhesion molecules
- learning
- microtubule cytoskeleton organization
- negative regulation of neuron differentiation
- positive regulation of adenosine receptor signaling pathway
- positive regulation of protein processing
- protein localization to juxtaparanode region of axon
- protein processing
- receptor internalization
- reduction of food intake in response to dietary excess
- regulation of astrocyte differentiation
- regulation of axon diameter
- regulation of cell morphogenesis
- regulation of neuronal synaptic plasticity
- synapse organization
- establishment of protein localization to juxtaparanode region of axon
- presynaptic membrane organization
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Fibronectin type III
- Immunoglobulin-like domain
- Immunoglobulin I-set
- Immunoglobulin-like fold
- Fibronectin type III superfamily
- Immunoglobulin-like domain superfamily
- Contactin-1/2, immunoglobulin domain 2
- Fibronectin type III domain
- Immunoglobulin I-set domain
- Immunoglobulin domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CNTN2 as an antibody target. Whether an autoantibody or antibody against CNTN2 could matter depends on whether native CNTN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CNTN2 is annotated at the cell surface, where native CNTN2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CNTN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...